Who are aspirin + celecoxib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Topical diclofenac sodium gel, alpha-blocker and NSAID, Tylenol and Ibuprofen only, morphine ,ketorolac, Voltaren® Gel, Prednisone and Aspirin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aspirin-celecoxib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

aspirin + celecoxib — Competitive Intelligence Brief

aspirin + celecoxib (aspirin + celecoxib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID) combination. Area: Rheumatology / Pain Management.

marketed Nonsteroidal anti-inflammatory drug (NSAID) combination COX-1 and COX-2 enzymes Rheumatology / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

aspirin + celecoxib (aspirin + celecoxib) — Seoul National University Hospital. This combination inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation through dual NSAID action.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
aspirin + celecoxib TARGET	aspirin + celecoxib	Seoul National University Hospital	marketed	Nonsteroidal anti-inflammatory drug (NSAID) combination	COX-1 and COX-2 enzymes
Topical diclofenac sodium gel	Topical diclofenac sodium gel	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2 enzymes
alpha-blocker and NSAID	alpha-blocker and NSAID	Samsung Medical Center	marketed	Alpha-blocker and NSAID combination	Alpha-1 adrenergic receptor; COX-1 and COX-2 enzymes
Tylenol and Ibuprofen only	Tylenol and Ibuprofen only	The Cooper Health System	marketed	Analgesic/Antipyretic combination (acetaminophen + NSAID)	Prostaglandin synthesis pathway; COX-1 and COX-2 enzymes
morphine ,ketorolac	morphine ,ketorolac	Jose Antonio Bernia Gil	marketed	Opioid analgesic + NSAID combination	Opioid receptors (μ, δ, κ); COX-1 and COX-2 enzymes
Voltaren® Gel	Voltaren® Gel	Glenmark Pharmaceuticals Ltd. India	marketed	Topical NSAID	COX-1 and COX-2 enzymes
Prednisone and Aspirin	Prednisone and Aspirin	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Corticosteroid and nonsteroidal anti-inflammatory drug (NSAID) combination	Glucocorticoid receptor (prednisone); Cyclooxygenase-1 and Cyclooxygenase-2 (aspirin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) combination class)

Seoul National University Hospital · 1 drug in this class
University Hospital, Basel, Switzerland · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). aspirin + celecoxib — Competitive Intelligence Brief. https://druglandscape.com/ci/aspirin-celecoxib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab